Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Infect Immun ; 64(11): 4520-4, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8890201

ABSTRACT

Antileukoprotease (ALP), or secretory leukocyte proteinase inhibitor, is an endogenous inhibitor of serine proteinases that is present in various external secretions. ALP, one of the major inhibitors of serine proteinases present in the human lung, is a potent reversible inhibitor of elastase and, to a lesser extent, of cathepsin G. In equine neutrophils, an antimicrobial polypeptide that has some of the characteristics of ALP has been identified (M. A. Couto, S. S. L. Harwig, J. S. Cullor, J. P. Hughes, and R. I. Lehrer, Infect. Immun. 60:5042-5047, 1992). This report, together with the cationic nature of ALP, led us to investigate the antimicrobial activity of ALP. ALP was shown to display marked in vitro antibacterial activity against Escherichia coli and Staphylococcus aureus. On a molar basis, the activity of ALP was lower than that of two other cationic antimicrobial polypeptides, lysozyme and defensin. ALP comprises two homologous domains: its proteinase-inhibitory activities are known to be located in the second COOH-terminal domain, and the function of its first NH2-terminal domain is largely unknown. Incubation of intact ALP or its isolated first domain with E. coli or S. aureus resulted in killing of these bacteria, whereas its second domain displayed very little antibacterial activity. Together these data suggest a putative antimicrobial role for the first domain of ALP and indicate that its antimicrobial activity may equip ALP to contribute to host defense against infection.


Subject(s)
Anti-Bacterial Agents/pharmacology , Escherichia coli/drug effects , Proteins/pharmacology , Serine Proteinase Inhibitors/pharmacology , Staphylococcus aureus/drug effects , Anti-Bacterial Agents/chemistry , Blood Proteins/pharmacology , Colony Count, Microbial , Defensins , Electrophoresis, Polyacrylamide Gel , Escherichia coli/growth & development , Humans , Hydrogen-Ion Concentration , Microbial Sensitivity Tests , Muramidase/pharmacology , Pancreatic Elastase/antagonists & inhibitors , Proteinase Inhibitory Proteins, Secretory , Proteins/chemistry , Recombinant Proteins/pharmacology , Staphylococcus aureus/growth & development
2.
Clin Chem ; 39(12): 2518-21, 1993 Dec.
Article in English | MEDLINE | ID: mdl-8252724

ABSTRACT

A method is described for a temperature-controlled ultrafiltration procedure to measure free cortisol in serum. A special thermometer with a sensor was developed, measuring the temperature directly in the ultrafiltration device. The sensor is screwed on the axis of the centrifuge rotor, and the centrifuge is placed in a temperature-controlled box so that the temperature of the sample is kept at 37 degrees C +/- 0.1 degrees C. The overall CV of the free cortisol assay ranges from 2.2% to 11.4%, of which the ultrafiltration contributes only 2.2-3.6%. Increasing amounts of cortisol-binding protein, as found in women using estrogen-containing oral contraceptives, have minor but significant effects on the free cortisol concentrations in serum. Serum free cortisol concentrations in a reference population (n = 114; central 95 percentiles) were 12-43 nmol/L (4-9.5% of total cortisol); in the group of the oral-contraceptive users (n = 27), the reference interval was 11-53 nmol/L (1.5-4.5%).


Subject(s)
Fluorescence Polarization Immunoassay , Hydrocortisone/blood , Ultrafiltration , Blood Preservation , Drug Stability , Female , Fluorescence Polarization Immunoassay/statistics & numerical data , Humans , Hydrogen-Ion Concentration , Male , Reference Values , Regression Analysis , Reproducibility of Results , Temperature , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL